TASCENSO ODT (fingolimod lauryl sulfate)
TASCENSO ODT is indicated for the treatment of Multiple Sclerosis; Clinically Isolated Syndrome; Relapsing-Remitting Disease; Secondary Progressive Disease.
How TASCENSO ODT Works
Fingolimod is metabolized into fingolimod-phosphate, an active metabolite that binds to sphingosine 1-phosphate receptors 1, 3, 4, and 5. This interaction prevents lymphocytes from leaving the lymph nodes, which reduces the number of these cells circulating in the peripheral blood. The drug's therapeutic effect in multiple sclerosis may be due to the resulting decrease in lymphocyte migration into the central nervous system.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2021-12-23
- Patent Cliff
- 2036
- Routes
- ORAL
- Dosage Forms
- TABLET, ORALLY DISINTEGRATING
TASCENSO ODT Approval History
What TASCENSO ODT Treats
4 indicationsTASCENSO ODT is approved for 4 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Multiple Sclerosis
- Clinically Isolated Syndrome
- Relapsing-Remitting Disease
- Secondary Progressive Disease
TASCENSO ODT Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in TASCENSO ODT's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications TASCENSO ODT treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to TASCENSO ODT
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TASCENSO ODT FDA Label Details
Indications & Usage
FDA Label (PDF)TASCENSO ODT is indicated for the treatment of Multiple Sclerosis; Clinically Isolated Syndrome; Relapsing-Remitting Disease; Secondary Progressive Disease.
TASCENSO ODT Patents & Exclusivity
Patents (3 active)
Pro Intelligence Preview
Deep insights for TASCENSO ODT
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2036
- • 12 active patents
Trial Analysis
- • 39 total trials
- • Stage: Mature
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment